On Wednesday, Swift Energy Co. (NYSE:SFY)’s shares surged 13.19% to $3.26.
Swift Energy, will report its first quarter financial results on Thursday, May 7, 2015 by issuing a news release before the market opens and conducting a conference call to talk about such results on that date at 9:00 a.m. CDT. To take part in this conference call, dial 877-420-2751 five to ten minutes before the planned start time and indicate your intention to take part in the Swift Energy conference call using Conference ID # 21569652. A digital replay of the call will also be accessible two hours after the call’s completion on May 7 until May 21, by dialing 855-859-2056 and using Conference ID # 21569652.
Swift Energy Company, an independent oil and gas company, attains, explores, develops, and operates oil and gas properties. The company focuses on the Eagle Ford trend of South Texas, in addition to the onshore and inland waters of Louisiana. As of December 31, 2014, it had estimated proved reserves of 193.8 million barrels of oil equivalent. Swift Energy Company was founded in 1979 and is headquartered in Houston, Texas.
Basic Energy Services, Inc. (NYSE:BAS)’s shares gained 12.61% to $9.29, during the last trading session on Wednesday.
Basic Energy Services, stated selected operating data for the month of March 2015. Basic’s well servicing rig count remained unchanged at 421. Well servicing rig hours for the month were 56,000 producing a rig utilization rate of 55%, contrast to 55% and 75% in February 2015 and March 2014, respectively.
During the month, Basic’s fluid service truck count reduced by 26 to 1,023. Fluid service truck hours for the month were 202,900 contrast to 184,100 and 211,000 in February 2015 and March 2014, respectively.
Drilling rig days for the month were 186 producing a rig utilization of 50%, contrast to 63% and 81% in February 2015 and March 2014, respectively.
Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. Its Completion and Remedial Services segment offers pumping services, such as cementing, acidizing, fracturing, nitrogen, and pressure testing; rental and fishing tools; coiled tubing; snubbing services; thru-tubing; cased-hole wireline services; and underbalanced drilling in low pressure and fluid sensitive reservoirs.
At the end of Wednesday’s trade, Sage Therapeutics, Inc. (NASDAQ:SAGE)’s shares gained 10.82% to $59.50, hitting its highest level.
Sage Therapeutics, declared the pricing of an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of $52.50 per share, before underwriting discounts. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock on the same terms and conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC are serving as co-managers. The offering is predictable to close on or about April 20, 2015, subject to customary closing conditions.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company’s lead product candidate comprises SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE).
Finally, Biodel Inc. (NASDAQ:BIOD), ended its Wednesday’s trading session with 10.68% gain, and closed at $1.14, hitting its lowest level.
Biodel, declared that it has priced a public offering of 32,608,696 shares of its common stock at a price of $0.92 per share. The offering is predictable to close on April 20, 2015, subject to customary closing conditions. In addition, Biodel has granted the underwriters a 30-day option to purchase up to 4,891,304 additional shares of common stock to cover over-allotments, if any.
William Blair and Ladenburg Thalmann are acting as joint book-running managers for the offering. Roth Capital Partners is acting as co-manager.
The gross proceeds to Biodel from this offering are predictable to be about $30,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by Biodel. All of the shares in the offering are being sold by Biodel. Biodel intends to use the net proceeds from the offering for operating costs, capital expenditures and for general corporate purposes, counting working capital.
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency administration (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
